• In July 2026, DexCom, Inc. received Health Canada authorization for its Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes, offering up to 15.5 days of wear, best-in-class accuracy with an overall MARD of 8.0%, and multiple app-based connectivity and data-sharing features.
• This approval not only extends DexCom’s CGM presence in Canada but also underscores how longer wear duration and fewer sensor changes may strengthen its competitive position in digitally integrated diabetes care.
• We’ll now examine how Health Canada’s authorization of the longer-wear Dexcom G7 15 Day system could influence DexCom’s broader investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

DexCom Investment Narrative Recap

To own DexCom, you need to believe continuous glucose monitoring stays central to diabetes care and that DexCom can keep its technology and ecosystem compelling. The Health Canada nod for the longer wear G7 15 Day in adults reinforces that product story, but it does not materially change the near term focus on converting new users and managing the risk of pricing pressure, particularly from potential CMS competitive bidding on CGMs.

The recent CONNECT trial results for Dexcom G7 in type 2 patients not using insulin feel especially relevant here. They speak directly to one of DexCom’s key catalysts: expanding beyond the traditional type 1 base into a much larger type 2 population, where payer coverage is ahead of actual CGM adoption and future growth depends on turning coverage into active, paying users.

But while longer wear and better data sharing can help, investors should also be aware that pricing pressure from potential CMS competitive bidding could...

DexCom's narrative projects $6.7 billion revenue and $1.4 billion earnings by 2029. This requires 11.6% yearly revenue growth and a roughly $0.5 billion earnings increase from $930.4 million.

Uncover how DexCom's forecasts yield a $85.24 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts see a tougher road, assuming revenue only reaches about US$6.5 billion and earnings about US$1.2 billion by 2029, so this new 15 day approval might eventually shift how pessimistic or optimistic you feel about adoption outside insulin intensive users.

Explore 6 other fair value estimates on DexCom - why the stock might be worth just $85.24!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.